Ap. Prof. Ing. Dr. Angelika Lahnsteiner
Division of Cancer (Epi-)Genetics, Dept. of Biosciences and Medical Biology
Center for Tumor Biology and Immunology (CTBI)
Paris Lodron University of Salzburg
Cancer Cluster Salzburg
Programm
“SNVs and DNA methylation as drivers of aberrant G4 folding in metabolic diseases”
The alarming increase in global obesity rates and their association with metabolic diseases (MetDs) and cancer represent a considerable burden on society, emphasizing the critical need to understand the underlying molecular mechanisms. Single nucleotide variants (SNVs) and aberrant DNA methylation are associated with disease development and progression and, in turn, can influence the stability and topology of alternative DNA structures such as G-quadruplexes (G4s). We hypothesize that this mechanism contributes to the progression from MetD to cancer and may help explain the increased cancer risk observed in patients with metabolic diseases.
By analyzing data from genome-wide association studies and epigenome-wide DNA methylation analyses, we identified several sites at which genetic or epigenetic alterations lead to changes in G4 formation and stability. Detailed in vitro characterization of a hypomethylated alternative promoter showed that loss of DNA methylation promotes G4 formation and activates the promoter element, whereas the methylated state does not support G4 formation and remains transcriptionally inactive. Similarly, disease-associated SNVs were found to alter G4 stability, and these stability changes were associated with alterations in gene expression. Notably, many of the identified sites are linked to metabolic and immune-system-related pathways. As G4s are known to act as important binding hubs for transcription factors, changes in the alternative DNA structure landscape also influences the binding of proteins to DNA.
Our findings provide new insights into the interplay between SNVs, DNA methylation, and alternative DNA structures in gene regulation. They identify G4s as potential molecular drivers of metabolic disease progression and suggest a mechanistic link that may also contribute to the increased susceptibility to cancer observed in patients with metabolic diseases.
Host: Johannes SCHMID
Contact for questions: Helmut KUBISTA